Previous business/academic article Next business/academic article
Academic Articles Awards > General Antitrust

Risky Business: Should the FDA Pay Attention to Pharmaceutical Prices?

David A. Hyman and William E. Kovacic, Regulation, Cato Institute, Winter 2017

See Bill Kovacic's resume See David A. Hyman's resume

Click here to read the full article online

People are angry about drug prices. What role, if any, should the FDA play in addressing this issue? Historically, the FDA’s answer has been “not our problem.” As the quality and safety agency, the FDA has repeatedly refused to get involved in drug pricing matters, even when its actions (and inactions) have contributed to the problem. We examine the circumstances under which the FDA should pay attention to pharmaceutical prices, and discuss the implications of it doing so.

Download our brochure